Risk of Worsening Renal Function With Nesiritide in Patients With Acutely Decompensated Heart Failure
By J. Sackner-Bernstein, H. Skopicki, Keith D. Aaronson. Circulation, 2005
761 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Hematology, Nephrology
View Paper: https://www.semanticscholar.org/paper/191e7e28f279e4d2d0a87d03f4851d285ed3fd7d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Hematology
In Nephrology
Citations in the corpus
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007, background): “concern has been raised about the adverse effect of these treatments on long-term clinical outcomes.(10-17) Volume overload remains a major cause of hospitalization and of continued morbidity among hospitalized patients,(18,19) and concern exists regarding the adverse renal impact of diuretic and ot”
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007, neutral): “7) [24-94] 65.”
- Cardiorenal syndrome. (2008, neutral): “Other medications requiring thorough considerations of pros and cons include diuretics, digitalis, calcium-channel blockers, and nesiritide (136–141).”
- Natriuretic Peptides: Their Structures, Receptors, Physiologic Functions and Therapeutic Applications (2009, result): “…not improve renal function in patients with chronic heart failure (Wang et al. 2004), but more damaging were two meta-analysis studies by Sackner-Bernstein and colleagues indicating that nesiritide worsened renal function and increased the likelihood of death (Sackner-Bernstein et al. 2005a, b).”
- Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. (2005, background): “There is concern, however, that patients treated with nesiritide are at heightened risk of worsening renal function.(5) Several studies have shown that an increase in serum creatinine levels, such as that observed with nesiritide, predicts a higher risk of death even when that increase is transient.”
- 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, methodology): “In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-based beta blockers should be used to reduce mortality (346-348).”